A Noninvasive and Highly Effective Inhaled Nanovaccine Based on Natural Polysaccharide for Lung Cancer Treatment
Authors:
- 2 August 2025
- journal article
- Published by Wiley in Advanced Materials
- Vol. 37 (42) , e04987
Abstract
Lung cancer is the most widespread malignancy globally and the leading cause of cancer‐related deaths, highlighting the need for innovative treatments. Herein, a novel inhaled vaccine carrier is presented by modifying dextran (Dex) with N , N ‐dimethylethylenediamine (DMEN) and 4‐(bromomethyl)phenylboronic acid (PBA) (Dex–DMEN–PBA, DDP). The optimized DDP demonstrates a potent adjuvant effect in promoting dendritic cell (DC) maturation by multiple signaling pathways. Moreover, the nanovaccine (DDP/Lewis lung carcinoma (LLC)) forms through electrostatic interactions between DDP and protein antigens derived from LLC cells. Upon inhalation, it induces DC maturation, T cell activation, and germinal center B cell activation in the thoracic lymph node. In the mouse model, the inhaled DDP/LLC nanovaccine displays impressive prophylactic effects against lung cancer, with 50% of mice alive after six months and 33% surviving a subsequent challenge, indicating strong long‐term immune memory. Remarkably, it surpasses subcutaneous vaccination, particularly in activating germinal center B cells and follicular helper T (Tfh) cells, and upregulating tissue‐resident memory T (T RM ) cells in the lung. This self‐adjuvant nanovaccine effectively prevents tumor growth and induces robust immune memory, offering valuable insight for treating lung cancer and related diseases.Keywords
Funding Information
- National Natural Science Foundation of China (52450010, 52325106, 52271248)
- Program of Shanghai Academic Research Leader (23XD1402900)
- Natural Science Foundation of Jiangsu Province (BK20240040)
This publication has 53 references indexed in Scilit:
- Topology‐Oriented Lymph Node Drainage of Dendritic Polymer‐TLR Agonist Conjugates to Enhance Vaccine ImmunogenicityAdvanced Materials, 2025
- Lung cancer research and treatment: global perspectives and strategic calls to actionAnnals of Oncology, 2024
- A Minimalist Pathogen‐Like Sugar Nanovaccine for Enhanced Cancer ImmunotherapyAdvanced Materials, 2024
- Systemic Multifunctional Nanovaccines for Potent Personalized Immunotherapy of Acute Myeloid LeukemiaAdvanced Materials, 2024
- Metal‐Free Atom Transfer Radical Polymerization to Prepare Recylable Micro‐Adjuvants for Dendritic Cell VaccineAngewandte Chemie International Edition, 2024
- A Novel Polymer Nanoparticle Polydimethyl Diallyl Ammonium Chloride as An Adjuvant Enhances the Immune Response of SARS‐CoV‐2 Subunit VaccineAdvanced Healthcare Materials, 2024
- Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor CellAdvanced Science, 2023
- Developing Next‐Generation Protein‐Based Vaccines Using High‐Affinity Glycan Ligand‐Decorated GlyconanoparticlesAdvanced Science, 2022
- Mucosal vaccine delivery: A focus on the breakthrough of specific barriersActa Pharmaceutica Sinica B, 2022
- Boronic acid-rich dendrimer for efficient intracellular peptide deliveryScience China Materials, 2019